{"id":64830,"date":"2026-05-09T14:58:02","date_gmt":"2026-05-09T06:58:02","guid":{"rendered":"https:\/\/flcube.com\/?p=64830"},"modified":"2026-05-09T14:58:03","modified_gmt":"2026-05-09T06:58:03","slug":"allergan-aesthetics-secures-first-in-china-nmpa-approval-for-juvederm-voluma-temple-indication","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64830","title":{"rendered":"Allergan Aesthetics Secures First-in-China NMPA Approval for Juv\u00e9derm VOLUMA Temple Indication"},"content":{"rendered":"\n

Allergan Aesthetics<\/strong>, an AbbVie<\/strong> (NYSE: ABBV<\/a>) company, announced it has received marketing approval from China’s National Medical Products Administration (NMPA)<\/strong> for Juv\u00e9derm VOLUMA with Lidocaine<\/strong> with a specific indication for the temple area. The cross-linked sodium hyaluronate gel for injection is now approved for supraperiosteal injection in the temporal region to improve temple hollowing, marking it as the first hyaluronic acid filler<\/strong> approved in China for this aesthetic indication.<\/p>\n\n\n\n

Regulatory Approval Details<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Product<\/strong><\/td>Juv\u00e9derm VOLUMA with Lidocaine<\/td><\/tr>
Indication<\/strong><\/td>Supraperiosteal injection in temporal region for temple hollowing improvement<\/td><\/tr>
Regulatory Agency<\/strong><\/td>National Medical Products Administration (NMPA), China<\/td><\/tr>
Approval Significance<\/strong><\/td>First hyaluronic acid filler approved in China for temple indication<\/td><\/tr>
Company<\/strong><\/td>Allergan Aesthetics (AbbVie subsidiary)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Pivotal Phase III Clinical Data<\/h2>\n\n\n\n

The NMPA approval was supported by results from a multi-center, randomized, blank-controlled, evaluator-blinded Phase III study conducted specifically in the Chinese population:<\/p>\n\n\n\n

Endpoint<\/th>Result<\/th><\/tr><\/thead>
Primary Endpoint<\/strong><\/td>ATHS (Aesthetic Temple Hollowing Scale) response rate<\/td><\/tr>
ATHS Response Rate<\/strong><\/td>90.5% at six months post-treatment<\/td><\/tr>
Investigator GAIS Improvement<\/strong><\/td>>92%<\/td><\/tr>
Subject GAIS Improvement<\/strong><\/td>>92%<\/td><\/tr>
Safety Profile<\/strong><\/td>Favorable safety and tolerability demonstrated<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The Global Aesthetic Improvement Scale (GAIS) scores exceeding 92% for both investigators and subjects indicate high levels of satisfaction with treatment outcomes from both clinical and patient perspectives.<\/p>\n\n\n\n

Market Impact & Strategic Context<\/h2>\n\n\n\n